Pipeline
Accelerated testing and development to benefit patients as soon as possible.
We have a first-in-category platform that enables acceleration of drug research and development.
Pipeline graph
Discovery
Lead Selection
Preclinical
Phase 1
Phase 2
-
KAN-001, targeting Checkpoint Refractory Cancers, Preclinical 75% completed In partnership with MD Anderson Cancer Center
KAN-001
Checkpoint Refractory Cancers
In partnership with MD Anderson Cancer CenterCancer immunotherapy has revolutionized cancer treatment, yet a significant proportion of patients do not respond. Our data, along with many other studies, suggest the constituents of the gut microbiome are critically important for the equilibrium of the immune system, which allows a positive immunotherapy response. We are developing KAN-001 as a synergistic therapy to prime the immune system and increase the overall response rate and survival in immunotherapy-eligible cancer patients.
-
KAN-001, targeting Checkpoint Naïve Cancers, Preclinical 25% completed
KAN-001
Checkpoint Naïve Cancers
KAN-001 is being developed to optimize the gut microbiome in ICI-naïve cancer patients, enhancing response and survival outcomes. By priming the gut and immune system before treatment, KAN-001 aims to reduce the risk of tumor escape and improve the safety and tolerability of ICIs, helping patients stay on their life-saving ICI therapy. With the the low-risk safety profile of microbiome therapies, KAN-001 has an opportunity to boost the effectiveness of ICIs from the start, improving both response rates and long-term outcomes.
-
KAN-004, targeting Checkpoint-induced Colitis, Preclinical 25% completed
KAN-004
Checkpoint-induced Colitis
Our early-stage clinical product is a live biotherapeutic product (LBP) made from a diverse microbial community, specifically designed to address a critical side effect of immune checkpoint inhibitor (ICI) therapies — colitis. As ICIs revolutionize cancer treatment, managing their associated immune-related adverse events, such as colitis, is essential for improving patient outcomes and quality of life. KAN-004 offers a novel, microbiome-based approach, aiming to restore gut health and reduce inflammation, providing hope for better-tolerated cancer treatments.
Harnessing the 9th organ system.
Our technology platforms can address all regulatory requirements and accelerate critical steps along the drug development pathway.
This will enable us to establish the microbiome as the vital 9th organ system, driving new insights, increasing legitimate therapeutic options, and ultimately improving personalized patient care.
Therapeutic Partnerships
We’re working with the University of Texas MD Anderson Cancer Center on treatments for immuno-therapy resistant cancers.
HiPR FISH Technology lets us see how the relationships inside the body react to each other.